GDP consulting for medicine transport and storage in Montenegro
GDP consulting for medicine transport and storage in Montenegro. Define responsibilities, temperature evidence, carrier controls and deviation handling.
Request an initial assessment
GDP consulting for medicine transport and storage in Montenegro. Define responsibilities, temperature evidence, carrier controls and deviation handling.
Request an initial assessment
GDP transport and storage must prove that the quality and integrity of the drug remain preserved from receipt to the warehouse until delivery to the customer. ConsultHQ helps wholesalers and pharmaceutical distributors to arrange storage and transport processes, temperature monitoring, qualification evidence and deviations according to current CInMED and EU GDP requirements.
The medicine may arrive without visible damage, but was exposed to unacceptable conditions during storage or transport.
This is precisely where the GDP risk arises.
It is not enough to have a cooling device, a logger or a temperature-controlled vehicle. The company must be able to demonstrate that the entire system provides reliable control and that there is a defined response when conditions deviate.
On July 22, 2026, CInMED published the current Good Practice Guidelines in the distribution of medicines for human use. During August, the Institute also published EU-harmonized procedures for GDP inspections, issuing certificates and standardized inspection documents.
The European basis remains the Guidelines of the European Commission 2013/C 343/01, based on Directive 2001/83/EC and related to the requirements introduced by Directive 2011/62/EU.
The EU GDP requires that the necessary storage conditions remain preserved during transport. The distributor must be able to demonstrate that the drug has not been exposed to conditions that may compromise its quality or integrity.
These operational controls are part of the wider GDP system in Montenegro. That is why we do not treat storage and transport as two separate systems.
We are looking at one distribution flow.
The exact scope of engagement depends on the product, warehouse, temperature regimes, transport model and existing quality system.
The project may include:
We do not introduce technical activities just because they exist in the generic GDP checklist.
We determine the volume according to the actual product and distribution risk.
A company may have a well-organized warehouse, but a weak transportation system.
The opposite can also be the case.
Vehicles and loggers work well, while storage mapping or temperature alarm response are not well documented.
That's why we follow the entire flow with gap analysis.
We check how the company connects reception, storage, shipment preparation, transportation and delivery to the customer.
The result is not a technical report without priority.
The client gets an overview of what is already working, where there is a GDP deviation and what needs to be resolved before the regulatory review.
The EU GDP requires that storage rooms are adapted to maintain the necessary conditions and protect medicines from temperature, moisture, light and other relevant external influences.
This does not mean that every wholesaler needs an identical technical solution.
During the inspection, we analyze the existing space, equipment and evidence by which the company confirms that the system works in the defined conditions.
In particular, we look at the relationship between:
The value is not that each document exists separately.
The value is that together they prove the control of space.
The temperature is not the same in every part of the larger storage area.
Rack layout, doors, air conditioning and other features can affect temperature distribution.
That is why during the GDP project we do not offer a universal rule where each sensor should be placed.
We review whether the existing temperature mapping corresponds to the space and whether it can justify the way in which routine monitoring is organized.
If the warehouse has been significantly changed, we also assess whether the existing qualification evidence still has value.
Such an approach follows a GDP logic based on risk, instead of a formal repetition of the same activity.
A large number of temperature records have no value if the measuring equipment is not under control.
The EU GDP requires regular maintenance and calibration of equipment used for temperature monitoring, and for equipment in transport it specifies regular intervals, at least once a year.
During the gap analysis, we also check the status of the device.
The goal is for the company to be able to associate the temperature result with the corresponding equipment and its qualification or calibration status.
If a deviation occurs, the reliability of that data becomes especially important.
The alarm system should indicate that the conditions have gone out of the defined range.
But GDP control is just beginning there.
During the implementation we review who receives the alarm, how the event is logged and how the information reaches the responsible person.
The system should enable the assessment of the affected products and the making of a documented decision.
We do not offer a universal solution for every temperature excursion.
Product status may be affected by drug type, duration of deviation, actual temperature and available stability data.
That is why a controlled assessment process is important.
Temperature-sensitive medicines have less room for uncontrolled deviation.
Therefore, the cold chain usually requires a more detailed qualification of the transport and storage system.
During the project we can review:
We do not look at each element separately.
The question is whether the combination of those elements proves the preservation of the necessary conditions from the beginning to the end of the transport.
The EU GDP mandates that the conditions defined by the manufacturer or specified on the packaging are maintained during transport. Transport should be planned through a risk-based approach.
That is why the transport system should not start with the question of which vehicle the company already has.
First you need to understand product requirements and distribution routes.
ConsultHQ reviews how these requirements are translated into transport controls.
If the company already has a functional system, we do not change it without reason.
If there is a gap between the drug requirements and the transport model, we define what needs to be corrected.
The same mileage does not mean the same risk.
Direct route and transport involving transhipment or temporary storage have different checkpoints.
The EU GDP particularly emphasizes the evaluation of routes to determine the necessary temperature control. During transshipment and transit storage, additional attention should be paid to the temperature, cleanliness and safety of intermediate locations.
During the engagement we can therefore review representative transport models.
The goal is not to complicate every delivery.
The goal is for greater risk to gain greater control.
The EU GDP requires that the choice of containers and packaging take into account the storage conditions, the quantity of the product, the expected temperature extremes and the maximum duration of transport, including possible transit storage.
Therefore, thermal packaging should not be treated as a universal box for every product and season.
During the GDP review, we analyze the existing qualification evidence and its connection with the actual transport scenario.
If the system is already qualified and used within documented limits, that is the basis we retain.
We ask for new evidence when a change or risk justifies it.
Article 116 of the Law on Medicines (Official Gazette Nos. 14/26 and 94/26) permits a wholesaler to contract transport to a business that is not itself a wholesaler only if that carrier is registered for transport and meets GDP requirements. Contractual control therefore covers registration, carrier qualification, temperature requirements, access to records, reporting of deviations and the right to review contracted activities. The wholesaler must be able to demonstrate control across the transport chain.
When a wholesaler outsources transport to an external provider, the GDP responsibilities of the wholesaler do not disappear with the transport contract.
EU GDP requires that the contract with the third party includes the relevant GDP requirements and that the transport partner knows the necessary conditions for the specific shipment.
That's why during the engagement we review the way the company qualifies and controls transporters.
The following are particularly important questions:
These responsibilities should be clear before the incident.
Excursion is not just a logistical problem.
It can affect the status of the product and therefore must have an appropriate GDP trace.
The EU GDP requires that temperature deviation or damage during transport be reported to the distributor and recipient and that there is a procedure to investigate and process it.
During the implementation, we therefore connect the deviation with the existing quality system.
This includes documenting the event, assessing the impact and taking appropriate corrective action when there is a systemic cause.
If the same type of excursion is repeated, the problem is no longer a single event.
It becomes a signal to inspect the system.
A new cold room can change the qualification status of the system.
The same applies to a new vehicle, another transporter, different packaging or a change of WMS.
That is why changes that can affect the quality of the medicine should be assessed in a controlled manner.
During the GDP project, we review whether change control covers such events.
Not every change needs a major validation activity.
But any relevant change needs an assessment proportionate to the risk.
A modern warehouse often uses a WMS or other computerized system for product locations, batches, deadlines, and statuses.
If such a system blocks unapproved goods or manages key GDP information, its reliability becomes relevant to the quality system.
That's why gap analysis can also include key digital controls.
The goal is not to replace a functional IT system with additional paper records.
The goal is to understand where the digital system represents GDP control and whether the company has enough evidence to trust it.
There may be products of different status in the warehouse.
Regular goods, returns, blocked products or products awaiting a decision should not be accidentally treated the same.
The EU GDP allows for physical segregation or an appropriate electronic system providing equivalent security.
During the review, we check whether the existing control separates the statuses clearly enough.
We do not introduce a physical quarantine zone if a valid electronic system already achieves the same goal and meets the requirements.
The solution should follow a realistic warehouse process.
The EU GDP states the principle first expiry, first out – FEFO for inventory rotation, while documenting justified exceptions.
In larger warehouses, this is often already controlled by the WMS.
Then there is no need to create a parallel manual procedure that duplicates the same work.
During the implementation, we check whether the existing system reliably controls product deadlines and statuses.
We then document the GDP request around the actual control.
Product can be properly stored for hours and then be unnecessarily exposed to outdoor conditions during loading.
That is why GDP control includes the transition between storage and transport.
During the inspection, we observe how the company organizes reception and shipping.
Temperature-sensitive products and periods of high outdoor temperatures deserve special attention.
The goal is not to complicate the ramp with additional procedures.
The goal is to reduce the uncontrolled time outside the defined conditions.
One of the best ways to evaluate a transportation system is to track a specific shipment.
From issuing from the warehouse to handing over to the recipient.
Thus, we can check whether the documentation, packaging, monitoring, transporter and proof of delivery work as one system.
This type of check often reveals gaps that a review of SOP documentation does not show.
After that, the findings are turned into concrete corrective actions.
The result of the engagement should be a system that can further maintain operations and quality.
Depending on the volume, the client receives:
Not every project needs to include all of the above.
Gap analysis determines what the company really needs.
CInMED issues the GDP certificate after checking the conditions, and the wholesaler must act according to the Guidelines of Good Practice in Distribution. Current requirements for GDP certificate and CAPA procedure after inspection are available on the Institute's official website.
That is why the equipment itself does not prove GDP compliance.
A temperature-controlled vehicle, a logger or a modern cold room must be part of a documented system.
Preparation for the GDP inspection therefore includes data, procedures and the way employees work.
Not only the technical specifications of the equipment.
A higher level of GDP control increases the cost of distribution.
That's a real limitation.
But the most expensive solution is not automatically the best.
The control should be proportionate to the product and the risk.
The problem arises when the company chooses cheaper logistics, and after the incident there is not enough data to prove what happened to the medicine.
Then the commercial problem turns into a quality problem.
That is why the GDP project seeks a balance between the necessary control and an operationally sustainable system.
If a company has been using qualified transport models for years without relevant deviations, we do not start with the assumption that they need to be replaced.
We first review the proof.
The same goes for storage.
Mapping, monitoring and existing equipment may be fully adequate.
We recommend a change when there is a gap according to current requirements, a process change or insufficient evidence that the existing system still controls the risk.
Thus, unnecessary investments are avoided.
A company may have ten minor documentation discrepancies and one serious cold chain problem.
Those two types of findings do not have the same priority.
That's why we start the project with a risk-based gap analysis.
ConsultHQ can review storage space, temperature, documentation, transport models and external logistics and define a realistic plan of activities.
The goal is an uninterrupted GDP system in which the company can prove that the quality of the medicine is preserved from the controlled warehouse to the proper delivery to the customer.
An initial assessment helps us define scope and next steps based on your actual business.
Request an initial assessment